Zoledronic Acid Replaces Zometa and Reclast on Specialty Injectable Drug List
Date Issued: 7/1/2013
As of July 1, 2013, Zometa (code J3487) and Reclast (J3488) have been removed from the Specialty Injectable Drug List as a result of a CMS J-Code edit. These drugs have been replaced with zoledronic acid (Q2051).
As a reminder, all injectable drug codes that are part of the EmblemHealth Injectable Drug Utilization Management Program require prior approval by ICORE. Prior approvals are valid for up to six months from the date they were approved.